BioNotebook: Halozyme falters; Baxter acquires Chatham; Celgene buys Acceleron shares; and IPOs lose momentum

Halozyme Therapeutics closed down 27.3% at $8.43 per share on 4 April after it revealed a temporary halt for an ongoing Phase II clinical trial testing the San Diego-based company's PEGPH20 in pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.